Preliminary results from phase I trials respectively evaluating RMC-6236, a pan-RAS inhibitor, and HRS-4642, a KRASG12D inhibitor, indicate that both are safe and show promising signs of antitumor activity. These are just two of the candidate RAS therapies in a burgeoning development space as the field looks ahead to drugs that hit more than just KRASG12C.

7 months ago

Journal

KRAS (KRAS proto-oncogene GTPase)

KRAS G12C • KRAS G12D • KRAS G12

RMC-6236 • HRS-4642

10ms

A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation (ESMO 2023)

Conclusions HRS-4642 showed a tolerable safety profile and preliminary anti-tumor activity in advanced solid tumors harboring KRAS G12D mutation. Dose escalation is ongoing and expected to proceed to dose expansion soon.

10 months ago

Clinical • P1 data • Late-breaking abstract • Metastases

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS G12D • RAS mutation

HRS-4642

over1year

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (clinicaltrials.gov)

P1, N=108, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting

over 1 year ago

Enrollment open • Metastases

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS G12D • KRAS G12

HRS-4642

over1year

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (clinicaltrials.gov)

P1, N=108, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.

over 1 year ago

New P1 trial

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS G12D • KRAS G12

HRS-4642